|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 227.01 USD | -0.19% |
|
-2.93% | -0.65% |
| 03-10 | AbbVie Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 11:20 AM | |
| 03-09 | AbbVie says CEO Robert Michael's 2025 total compensation was $32.5 million - SEC filing | RE |
Company Valuation: AbbVie Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 239,371 | 285,707 | 273,605 | 314,021 | 403,830 | 401,392 | - | - |
| Change | - | 19.36% | -4.24% | 14.77% | 28.6% | -0.6% | - | - |
| Enterprise Value (EV) 1 | 306,225 | 339,749 | 320,176 | 375,610 | 463,570 | 452,804 | 440,302 | 427,753 |
| Change | - | 10.95% | -5.76% | 17.31% | 23.42% | -2.32% | -2.76% | -2.85% |
| P/E ratio | 21x | 24.4x | 57x | 74.4x | 96.8x | 24.7x | 20.2x | 17.3x |
| PBR | 15.5x | 16.6x | 26.5x | 94.8x | -124x | 71.2x | 31.6x | 18.4x |
| PEG | - | 8.74x | -1x | -6.1x | -77.12x | 0x | 0.9x | 1x |
| Capitalization / Revenue | 4.27x | 4.92x | 5.04x | 5.57x | 6.6x | 5.98x | 5.53x | 5.16x |
| EV / Revenue | 5.46x | 5.85x | 5.89x | 6.67x | 7.58x | 6.75x | 6.07x | 5.5x |
| EV / EBITDA | 10.6x | 11x | 12.5x | 15.6x | 18.9x | 13.5x | 12x | 10.7x |
| EV / EBIT | 10.9x | 11.3x | 12.9x | 16.1x | 19.5x | 13.9x | 12.2x | 10.8x |
| EV / FCF | 13.9x | 14x | 14.5x | 21.1x | 26x | 18.4x | 15.6x | 13.9x |
| FCF Yield | 7.18% | 7.14% | 6.89% | 4.75% | 3.84% | 5.43% | 6.41% | 7.21% |
| Dividend per Share 2 | 5.31 | 5.71 | 5.99 | 6.29 | 6.65 | 6.932 | 7.204 | 7.626 |
| Rate of return | 3.92% | 3.53% | 3.87% | 3.54% | 2.91% | 3.05% | 3.17% | 3.36% |
| EPS 2 | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 | 9.208 | 11.26 | 13.16 |
| Distribution rate | 82.3% | 86.1% | 220% | 263% | 282% | 75.3% | 64% | 58% |
| Net sales 1 | 56,122 | 58,054 | 54,318 | 56,334 | 61,160 | 67,076 | 72,530 | 77,742 |
| EBITDA 1 | 29,018 | 30,961 | 25,545 | 24,104 | 24,483 | 33,422 | 36,793 | 40,051 |
| EBIT 1 | 28,215 | 30,183 | 24,793 | 23,340 | 23,721 | 32,586 | 36,044 | 39,485 |
| Net income 1 | 11,542 | 11,836 | 4,863 | 4,278 | 4,226 | 17,187 | 20,041 | 22,812 |
| Net Debt 1 | 66,854 | 54,042 | 46,571 | 61,589 | 59,740 | 51,411 | 38,910 | 26,361 |
| Reference price 2 | 135.40 | 161.61 | 154.97 | 177.70 | 228.49 | 227.01 | 227.01 | 227.01 |
| Nbr of stocks (in thousands) | 1,767,880 | 1,767,880 | 1,765,537 | 1,767,140 | 1,767,385 | 1,768,169 | - | - |
| Announcement Date | 02/02/22 | 09/02/23 | 02/02/24 | 31/01/25 | 04/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 24.65x | 6.75x | 13.55x | 3.05% | 401B | |
| 29.43x | 11.08x | 22.26x | 0.66% | 895B | |
| 25.86x | 6.02x | 16.39x | 2.17% | 587B | |
| 18.04x | 4.39x | 10.87x | 3% | 345B | |
| 21.41x | 5.76x | 14.24x | 2.81% | 300B | |
| 24.8x | 5.16x | 14.3x | 1.69% | 306B | |
| 27.37x | 4.79x | 14.99x | 2.88% | 289B | |
| 25.26x | 6.39x | 11.37x | 2.67% | 202B | |
| 20.59x | 6.26x | 11.33x | 2.19% | 184B | |
| 11.53x | 4.21x | 8.77x | 4.36% | 171B | |
| Average | 22.90x | 6.08x | 13.81x | 2.55% | 368.14B | |
| Weighted average by Cap. | 24.57x | 6.94x | 15.65x | 2.18% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- ABBV Stock
- Valuation AbbVie Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition